389 related articles for article (PubMed ID: 25585954)
1. Quality and safety requirements for sustainable phage therapy products.
Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G
Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954
[TBL] [Abstract][Full Text] [Related]
2. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
Viertel TM; Ritter K; Horz HP
J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
[TBL] [Abstract][Full Text] [Related]
3. European regulatory aspects of phage therapy: magistral phage preparations.
Verbeken G; Pirnay JP
Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
[TBL] [Abstract][Full Text] [Related]
4. Phage choice, isolation, and preparation for phage therapy.
Gill JJ; Hyman P
Curr Pharm Biotechnol; 2010 Jan; 11(1):2-14. PubMed ID: 20214604
[TBL] [Abstract][Full Text] [Related]
5. What is needed for phage therapy to become a reality in Western medicine?
Brüssow H
Virology; 2012 Dec; 434(2):138-42. PubMed ID: 23059181
[TBL] [Abstract][Full Text] [Related]
6. Phage cocktails and the future of phage therapy.
Chan BK; Abedon ST; Loc-Carrillo C
Future Microbiol; 2013 Jun; 8(6):769-83. PubMed ID: 23701332
[TBL] [Abstract][Full Text] [Related]
7. Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.
Verbeken G; Huys I; De Vos D; De Coninck A; Roseeuw D; Kets E; Vanderkelen A; Draye JP; Rose T; Jennes S; Ceulemans C; Pirnay JP
FEMS Microbiol Lett; 2016 Feb; 363(4):. PubMed ID: 26678555
[TBL] [Abstract][Full Text] [Related]
8. Biofilm control with natural and genetically-modified phages.
Motlagh AM; Bhattacharjee AS; Goel R
World J Microbiol Biotechnol; 2016 Apr; 32(4):67. PubMed ID: 26931607
[TBL] [Abstract][Full Text] [Related]
9. Ameliorating the antimicrobial resistance crisis: phage therapy.
Saha D; Mukherjee R
IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
[TBL] [Abstract][Full Text] [Related]
10. Evolutionary Rationale for Phages as Complements of Antibiotics.
Torres-Barceló C; Hochberg ME
Trends Microbiol; 2016 Apr; 24(4):249-256. PubMed ID: 26786863
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of phage therapy via the intravenous route.
Speck P; Smithyman A
FEMS Microbiol Lett; 2016 Feb; 363(3):. PubMed ID: 26691737
[TBL] [Abstract][Full Text] [Related]
12. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
[TBL] [Abstract][Full Text] [Related]
13. Clinical aspects of phage therapy.
Międzybrodzki R; Borysowski J; Weber-Dąbrowska B; Fortuna W; Letkiewicz S; Szufnarowski K; Pawełczyk Z; Rogóż P; Kłak M; Wojtasik E; Górski A
Adv Virus Res; 2012; 83():73-121. PubMed ID: 22748809
[TBL] [Abstract][Full Text] [Related]
14. Computational models of populations of bacteria and lytic phage.
Krysiak-Baltyn K; Martin GJ; Stickland AD; Scales PJ; Gras SL
Crit Rev Microbiol; 2016 Nov; 42(6):942-68. PubMed ID: 26828960
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
Knoll BM; Mylonakis E
Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
[TBL] [Abstract][Full Text] [Related]
16. Phages and their potential to modulate the microbiome and immunity.
Federici S; Nobs SP; Elinav E
Cell Mol Immunol; 2021 Apr; 18(4):889-904. PubMed ID: 32901128
[TBL] [Abstract][Full Text] [Related]
17. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis.
Golkar Z; Bagasra O; Pace DG
J Infect Dev Ctries; 2014 Feb; 8(2):129-36. PubMed ID: 24518621
[TBL] [Abstract][Full Text] [Related]
18. Phages & antibiotic resistance: are the most abundant entities on earth ready for a comeback?
Hill C; Mills S; Ross RP
Future Microbiol; 2018 May; 13():711-726. PubMed ID: 29792526
[TBL] [Abstract][Full Text] [Related]
19. The perspectives of the application of phage therapy in chronic bacterial prostatitis.
Letkiewicz S; Międzybrodzki R; Kłak M; Jończyk E; Weber-Dąbrowska B; Górski A
FEMS Immunol Med Microbiol; 2010 Nov; 60(2):99-112. PubMed ID: 20698884
[TBL] [Abstract][Full Text] [Related]
20. [Possibilities of bacteriophage therapy].
Skurnik M; Kiljunen S
Duodecim; 2016; 132(8):712-9. PubMed ID: 27244930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
